Abbott to Acquire Exact Sciences for $21 Billion - WSJ

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/business/deals/abbott-to-acquire-exact-sciences-for-21-billion-8147b973 By and Updated Nov. 20, 2025 10:08 am ET Listen (4 min) Quick Summary Abbott Laboratories will acquire Exact Sciences for approximately $21 billion, with shareholders receiving $105 per share. The acquisition provides Abbott access to the expanding cancer screening market, adding Exact Sciences’ Cologuard test. Exact Sciences’ projected revenue of over $3 billion will boost Abbott’s annual diagnostics sales beyond $12 billion. An artificial-intelligence tool created this summary, which was based on the text of the article and checked by an editor. Read more about how we use artificial intelligence in our journa

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/business/deals/abbott-to-acquire-exact-sciences-for-21-billion-8147b973 By and Updated Nov. 20, 2025 10:08 am ET Listen (4 min) Quick Summary Abbott Laboratories will acquire Exact Sciences for approximately $21 billion, with shareholders receiving $105 per share. The acquisition provides A